LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved.Dis Colon Rectum疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40626521无 PMCID | 2025-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.J Natl Cancer InstAI 判定该论文不进入自动 KM 提取:This is a secondary analysis of quality of life trajectories within a phase III trial, not a primary report of the trial's efficacy or safety results. | PMID 40700618PMC12505141 | 2025-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.JAMA Intern MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40758358PMC12322823 | 2025-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial.JAMA OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40773220PMC12332761 | 2025-Oct-01 | 0.95 | The record describes a phase 3 randomized trial in oncology (nasopharyngeal cancer patients) but does not meet the core eligibility criteria. The intervention is a topical antibiotic (mupirocin) for preventing radiation-induced oral mucositis, not a systemic anti-cancer drug therapy. Furthermore, the primary endpoint is the incidence of a toxicity (grade ≥3 mucositis), not a time-to-event efficacy endpoint such as OS, PFS, or DFS, and no Kaplan-Meier analysis or hazard ratio is reported. Therefore, it is excluded. | 无 KM 图 |
| Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40839373PMC12371550 | 2025-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.JAMA Otolaryngol Head Neck Surg疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40875250PMC12395356 | 2025-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Dexmedetomidine for Analgesia in Nonintubated Patients With Traumatic Rib Fractures: A Randomized Clinical Trial.JAMA SurgPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40900569PMC12409648 | 2025-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40912057无 PMCID | 2025-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40986647无 PMCID | 2025-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.JAMA Netw Open | PMID 41032300PMC12489695 | 2025-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.BMC Cancer入排复审未纳入:The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR). The primary endpoint is a binary proportion (nausea-free rate). | PMID 41034823PMC12486796 | 2025-Oct-01 | 0.95 | The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR). The primary endpoint is a binary proportion (nausea-free rate). | 无 KM 图 |
| Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials.Int J Neuropsychopharmacol已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 multi panel km。 | PMID 41055581PMC12554155 | 2025-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study.Oncologist疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:AI 判定为 other;Figure 3.:非 KM 图。 | PMID 41124598PMC12557321 | 2025-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Prenatal Intravenous Iron and Child Growth: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other。 | PMID 41148141PMC12569709 | 2025-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.Eur UrolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39317633无 PMCID | 2025-Oct | 0.85 | The record describes a Phase III randomized trial of a drug combination in oncology, but the reported results are exclusively patient-reported outcomes (quality of life, pain, side-effect bother) and do not include a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an associated Kaplan-Meier analysis or hazard ratio. Therefore, it does not meet the criterion for a time-to-event efficacy endpoint. | 无 KM 图 |
| Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.Clin Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39909280无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fractional flow reserve or OCT to guide management of complex and noncomplex angiographically intermediate coronary stenosis.Rev Esp Cardiol (Engl Ed)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40107654无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Complex, low-intensity, individualised naturalistic developmental behavioural intervention in toddlers and pre-schoolers with autism spectrum disorder: The multicentre, observer-blind, parallel-group randomised-controlled A-FFIP trial.J Child Psychol Psychiatry已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 forest plot;Figure 3:AI 判定为 other。 | PMID 40135359PMC12447682 | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40222621无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.Clin Lymphoma Myeloma Leuk疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40360369无 PMCID | 2025-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40393861无 PMCID | 2025-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease.J Clin Pharmacol已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40401357PMC12484422 | 2025-Oct | 0.90 | The study is a Phase III randomized controlled trial of a drug (etrolizumab) but is for Crohn's disease, a non-oncology condition. The primary endpoints are categorical (remission, improvement) analyzed via logistic regression, not time-to-event endpoints like OS/PFS/DFS with Kaplan-Meier or HR. | 无 KM 图 |
| Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.Leuk Lymphoma疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40407269无 PMCID | 2025-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40460988无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40467365无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40473109无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40505670无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.J Thromb Haemost入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 40523501无 PMCID | 2025-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience.Addiction已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。 | PMID 40538333PMC12426361 | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.Ann OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40541863无 PMCID | 2025-Oct | 0.95 | The study is a Phase III randomized trial with a drug intervention, but the reported outcomes are exclusively health-related quality of life (HRQoL) measures (EORTC QLQ-C15-PAL, EQ-5D, IES). No time-to-event efficacy endpoints (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analyses are mentioned in the title, abstract, or metadata. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study.Fertil SterilPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40543832无 PMCID | 2025-Oct | 0.90 | The study is a randomized, phase 3, drug-intervention trial with original results, but it addresses a benign condition (uterine fibroids) and does not use a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for a malignant neoplasm trial with a primary time-to-event endpoint. | 无 KM 图 |
| Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40544121无 PMCID | 2025-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes-An analysis of COMPARE trial data.Am J Transplant疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40550469无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma.J Aerosol Med Pulm Drug DelivPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40551410无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40555305无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40578381无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.CPT Pharmacometrics Syst Pharmacol | PMID 40613748PMC12521056 | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.Leuk Lymphoma疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::CONSORT/入组流程图;Figure 2::非 KM 图;Figure 3::非 KM 图。 | PMID 40632607PMC12321088 | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?Breast已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图。 | PMID 40633461PMC12273582 | 2025-Oct | 0.70 | The record describes a secondary/prognostic analysis of trial data, not a primary or key secondary report of a drug intervention's time-to-event efficacy outcome (e.g., OS, PFS, DFS with KM/HR). The time-to-event criterion is not met. | 无 KM 图 |
| Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40633690无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Results of a Randomized Augmented Intensification Phase in Acute Lymphoblastic Leukemia in Children in Argentina: GATLA 2010 ALL IC Trial.Pediatr Blood CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40635183无 PMCID | 2025-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40639766无 PMCID | 2025-Oct | 0.95 | This is a Phase III randomized controlled trial report on urinary incontinence after salvage radiotherapy for prostate cancer. While it meets the criteria for oncology, human subjects, randomized design, and definitive phase, it does not report the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. It is a secondary report focused on a patient-reported outcome (quality of life/toxicity). | 无 KM 图 |
| A phase II pilot randomized controlled trial of an integrated stepped collaborative care intervention for patients awaiting kidney transplantation (CARES-transplant).J Behav Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40643797无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40680761无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial.CNS Drugs疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other。 | PMID 40681915PMC12423206 | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.Prostate已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 40686005PMC12366761 | 2025-Oct | 0.90 | The record is from a Phase III randomized trial (NRG/RTOG 9601) in prostate cancer with a drug intervention (bicalutamide + RT vs. RT alone) and time-to-event endpoints (OS, DSS). However, this specific abstract reports a subgroup/prognostic analysis investigating the impact of lymph node yield on outcomes, not the primary efficacy results of the trial. It is a secondary analysis of the trial data, not the original formal report of the trial's primary or key secondary efficacy findings. | 无 KM 图 |
| Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.J Clin Oncol | PMID 40690727PMC12456192 | 2025-Oct | 0.95 | The study is an oncology Phase III randomized trial in humans with a primary time-to-event endpoint (DFS) and reports original results. However, it is excluded because it does not involve a drug-containing intervention, comparing only surgical procedures. | 已完成 |
| Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.Mult Scler Relat DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40700861无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Phase 3 Active-Controlled Trial of Liposomal Bupivacaine via Adductor Canal Block for Total Knee Arthroplasty.J ArthroplastyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40701284无 PMCID | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40704485PMC12409197 | 2025-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |